eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
4/2019
vol. 23
 
Share:
Send email
Share:
abstract:
Original paper

Cancer immunotherapy experience in the Integral Oncology Centre “Diana Laura Riojas de Colosio”, Médica Sur Hospital

Ricardo Fernández-Ferreira
1
,
Daniel Motola-Kuba
2
,
Ileana Mackinney-Novelo
2
,
José Manuel Ruiz-Morales
2
,
María Eugenia Torres-Pérez
1

  1. Internal Medicine Department, Médica Sur Hospital, Mexico City, Mexico
  2. Oncology Medicine Department, Integral Oncology Centre “Diana Laura Riojas de Colosio”, Médica Sur Hospital, Mexico City, Mexico
Contemp Oncol (Pozn) 2019; 23 (4): 239-246
DOI: https://doi.org/10.5114/wo.2019.91534
Online publish date: 2019/12/30
View full text Get citation
 
PlumX metrics:
Introduction
The use of immunotherapy in Mexico has been used since 2012 with ipilimumab and since 2015 with nivolumab and pembrolizumab, so it is a matter of necessity to know the experience of these drugs.

Material and methods
An observational, descriptive, cross-sectional, and retrospective study was performed in Médica Sur Hospital, where with dossiers from 2012 to June 2018 patients with metastatic cancer who received immunotherapy with ipilimumab, nivolumab, and pembrolizumab for six months were evaluated, searching as principal outcomes the adverse effects of those drugs and as secondary outcomes the response to treatment.

Results
Seventy subjects fulfilled the inclusion criteria for the study, and 42 (60%) were women with an average age of 60.73 ±13.64 years (16–82 years). The pathologies that received immunotherapy were the following: melanoma and lung cancer. The most frequent clinical and laboratory adverse effects were as follows: fatigue – 32 (45.71%), asthaenia – 30 (42%), nausea – 8 (11.4%), diarrhoea – 8 (11.4%), and rash – 7 (10%). The worst adverse effects were respiratory and endocrinological: pneumonitis – 10 (14.28%), hypothyroidism – 4 (5.71%), hyperglycaemia – 1 (1.4%), and hypophysitis – 2 (2.9%). With respect to treatment response: complete response – 8 (11.4%), partial response – 11 (15.71%), stable disease – 33 (47.14%), and disease progression – 19 (27.14%).

Conclusions
The most common adverse effects did not condition the suspension of treatment or increase in intra-hospital stay, but there were some adverse effects that actually had an impact on evolution, hospital stay, and mortality.

keywords:

cancer, immunotherapy, ipilimumab, nivolumab, pembrolizumab
FEATURED PRODUCTS
BOOKS
• Genetyka i leczenie chłoniaka rozlanego z dużych komórek B (DLBCL)
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.